YAP1 and hepatocellular carcinoma: Chen et al. [66] found that the level of miR-590-5p negatively correlates with YAP expression in HCC, which is resistant to adriamycin (also known as doxorubicin), the most common first-line chemotherapeutic agent for transarterial chemoembolization [66].